Abstract
The definition of poorly differentiated thyroid carcinoma has been the source of great controversy in the pathology literature.1 Many definitions and schemes have been proposed, but little consensus exists about what defines a poorly differentiated thyroid carcinoma (PDTCA). Because of this, the clinical behavior is not well defined and the clinicopathologic features affecting prognosis remain largely unknown.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Volante M, Collini P, Nikiforov Y, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31(8):1256–1264.
Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg. 1997;174(5):462–468.
Akslen LA, LiVolsi VA. Poorly differentiated thyroid carcinoma - it is important. Am J Surg Pathol. 2000;24(2):310–313.
Patel KN, Shaha AR. Locally advanced thyroid cancer. Curr Opin Otolaryngol Head Neck Surg. 2005;13(2):112–116.
Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol. 2005;63(1):87–93.
Volante M, Landolfi S, Chiusa P, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer. 2004;100(5):950–957.
Nishiyama RH. Another dissertation on poorly differentiated carcinomas: is it really necessary? Adv Anat Pathol. 1999;6(5):281–286.
Albores-Saavedra J, Carrick K. Where to set the threshold between well differentiated and poorly differentiated follicular carcinomas of the thyroid. Endocr Pathol. 2004;15(4):297–305.
Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330–1335.
Sanders Jr EM, Jr LiVolsi V, Brierly J, et al. An evidence-based review of poorly differentiated thyroid cancer. World J Surg. 2007;31(5):934–945.
Pilotti S, Collini P, Mariani L, et al. Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns? Semin Diagn Pathol. 1995;12(3):249–255.
Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol. 2004;86(1):44–54.
Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer. 1983;52(10):1849–1855.
Yamashita H, Noguchi Y, Noguchi S, et al. Significance of an insular component in follicular thyroid carcinoma with distant metastasis at initial presentation. Endocr Pathol. 2005;16(1):41–48.
Volante M, Cavallo GP, Papotti M. Prognostic factors of clinical interest in poorly differentiated carcinomas of the thyroid. Endocr Pathol. 2004;15(4):313–317.
Carcangiu ML, Zampi G, Rosai J. Poorly differentiated (“insular”) thyroid carcinoma. A reinterpretation of Langhans’ “wuchernde Struma”. Am J Surg Pathol. 1984;8(9):655–668.
Chao TC, Lin JD, Chen MF. Insular carcinoma: infrequent subtype of thyroid cancer with aggressive clinical course. World J Surg. 2004;28(4):393–396.
Pilotti S, Collini P, Mariani L, et al. Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland. Am J Surg Pathol. 1997;21(12):1466–1473.
Falvo L, Catania A, Diandrea V, et al. Prognostic factors of insular versus papillary/follicular thyroid carcinoma. Am Surg. 2004;70(5):461–466.
Collini P, Sampietro G, Rosai J, et al. Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma. Virchows Arch. 2003;442(1):71–76.
Sobrinho-Simoes M, Sambade C, Fonseca E, et al. Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol. 2002;10(2):123–131.
Sasaki A, Daa T, Kashima K, et al. Insular component as a risk factor of thyroid carcinoma. Pathol Int. 1996;46(12):939–946.
Hiltzik DD, Carlson DL, Tuttle RM, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer. 2006;106(6):1286–1295.
Lam KY, Lo CY, Chan KW, et al. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg. 2000;231(3):329–338.
Takeuchi Y, Das T, Kashima K, et al. Mutations of p53 in thyroid carcinoma with an insular component. Thyroid. 1999;9(4):377–381.
Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369(9574):1731–1741.
Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev. 2007;17(1):3–7.
Broecker-Preuss M, Sheiu SY, Worm K, et al. Expression and mutation analysis of the tyrosine kinase c-kit in poorly differentiated and anaplastic thyroid carcinoma. Horm Metab Res. 2008;40(10):685–691.
Pulcrano M, Boukheris H, Talbot M, et al. Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid. 2007;17(7):639–646.
Montero-Conde C, Martin-Campos JM, Lerma E, et al. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene. 2008;27(11):1554–1561.
Rodrigues RF, Roque L, King T, et al. Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines. Br J Cancer. 2007;96(8):1237–1245.
Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 2007;14(2):719–729.
Tallini G, Garcia-Rostan G, Herreo A, et al. Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol. 1999;23(6):678–685.
Garcia-Rostan G, Camp RL, Herrero A, et al. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol. 2001;158(3):987–996.
Garcia-Rostan G, Tallini G, Herrero A, et al. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999;59(8):1811–1815.
Smith LW. Certain so-called sarcomas of the thyroid. Arch Pathol. 1930;10:524–530.
Hutter RV, Tollefson HR, DeCosse J, et al. Spindle and giant cell metaplasia in papillary carcinoma of the thyroid. Am J Surg. 1965;110(4):660–668.
Maddox WA, Knott HW, Dowling EA. Carcinoma of the thyroid: review of fifteen years’ experience. 1. Origin of spindle and giant cell carcinoma. 2. Occurrence of thyroid cancer in ectopic thyroid tissue. Am Surg. 1971;37(11):653–660.
Bronner MP, LiVolsi VA. Spindle cell squamous carcinoma of the thyroid: an unusual anaplastic tumor associated with tall cell papillary cancer. Mod Pathol. 1991;4(5):637–643.
Wolf BC, Sheahan K, DeCosste D, et al. Immunohistochemical analysis of small cell tumors of the thyroid gland: an Eastern Cooperative Oncology Group study. Hum Pathol. 1992;23(11):1252–1261.
Mendelsohn G, Baylin SB, Bigner SH, et al. Anaplastic variants of medullary thyroid carcinoma: a light-microscopic and immunohistochemical study. Am J Surg Pathol. 1980;4(4):333–341.
O’Neill JP, O’Neill B, Conaron C, et al. Anaplastic (undifferentiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease. J Laryngol Otol. 2005;119(8):585–591.
Jiang JY, Tseng FY. Prognostic factors of anaplastic thyroid carcinoma. J Endocrinol Invest. 2006;29(1):11–17.
Aratake Y, Nomura H, Katami T, et al. Coexistent anaplastic and differentiated thyroid carcinoma. Am J Clin Pathol. 2006;125(3):399–406.
Hunt JL. Unusual thyroid tumors: a review of pathologic and molecular diagnosis. Expert Rev Mol Diagn. 2005;5(5):725–734.
Besic N, Hocevar M, Zogjnar J, et al. Prognostic factors in anaplastic carcinoma of the thyroid - a multivariate survival analysis of 188 patients. Langenbecks Arch Surg. 2005;390(3):203–208.
Goutsouliak V, Hay JH. Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. Clin Oncol (R Coll Radiol). 2005;17(2):75–78.
Yau T, Lo CY, Epstein RJ, et al. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol. 2008;15(9):2500–2505.
Lai ML, Faa G, Senes C, et al. Rhabdoid tumor of the thyroid gland: a variant of anaplastic carcinoma. Arch Pathol Lab Med. 2005;129(3):e55-e57.
Carda C, Ferrer J, Vilanova M, et al. Anaplastic carcinoma of the thyroid with rhabdomyosarcomatous differentiation: a report of two cases. Virchows Arch. 2005;446(1):46–51.
Sato K, Waseda R, Tatsuzawa Y, et al. Papillary thyroid carcinoma with anaplastic transformation showing a rhabdoid phenotype solely in the cervical lymph node metastasis. Pathol Res Pract. 2006;202(1):55–59.
Carcangiu ML, Steeper T, Zampi G, et al. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol. 1985;83(2):135–158.
Shikama Y, Mizukami H, Yagihashi N, et al. Spindle cell metaplasia arising in thyroid adenoma: characterization of its pathology and differential diagnosis. J Endocrinol Invest. 2006;29(2):168–171.
Aker FV, Bas Y, Ozkara S, et al. Spindle cell metaplasia in follicular adenoma of the thyroid gland: case report and review of the literature. Endocr J. 2004;51(5):457–461.
Vergilio J, Baloch ZW, LiVolsi VA. Spindle cell metaplasia of the thyroid arising in association with papillary carcinoma and follicular adenoma. Am J Clin Pathol. 2002;117(2):199–204.
Baloch ZW, Wu H, LiVolsi VA. Post-fine-needle aspiration spindle cell nodules of the thyroid (PSCNT). Am J Clin Pathol. 1999;111(1):70–74.
Chan JK, Carcangiu ML, Rosai J. Papillary carcinoma of thyroid with exuberant nodular fasciitis-like stroma: report of three cases. Am J Clin Pathol. 1991;95(3):309–314.
Naganuma H, Iwama N, Nakamura Y, et al. Papillary carcinoma of the thyroid gland forming a myofibroblastic nodular tumor: report of two cases and review of the literature. Pathol Int. 2002;52(1):54–58.
Wan SK, Chan JK, Tang SK. Paucicellular variant of anaplastic thyroid carcinoma. A mimic of Reidel’s thyroiditis. Am J Clin Pathol. 1996;105(4):388–393.
Roka S, Kojnek G, Schuller J, et al. Carcinoma showing thymic-like elements - a rare malignancy of the thyroid gland. Br J Surg. 2004;91(2):142–145.
Dorfman DM, Shahsafaei A, Miyauchi A. Intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) exhibits CD5 immunoreactivity: new evidence for thymic differentiation. Histopathology. 1998;32(2):104–109.
Berezowski K, Grimes M, Gal AA, et al. CD5 immunorea-ctivity of epithelial cells in thymic carcinoma and CASTLE using paraffin-embedded tissue. Am J Clin Pathol. 1996;106(4):483–486.
Chan JK, Rosai J. Tumors of the neck showing thymic or related branchial pouch differentiation: a unifying concept. Hum Pathol. 1991;22(4):349–367.
Erickson ML, Tapia E, Moreno ER, et al. Early metastasizing spindle epithelial tumor with thymus-like differentiation (SETTLE) of the thyroid. Pediatr Dev Pathol. 2005;8(5):599–606.
Booya F, Sebo TJ, Kasperbauer JL, et al. Primary squamous cell carcinoma of the thyroid: report of ten cases. Thyroid. 2006;16(1):89–93.
Rodriguez I, Ayala E, Caballero C, et al. Solitary fibrous tumor of the thyroid gland: report of seven cases. Am J Surg Pathol. 2001;25(11):1424–1428.
Papi G, Corrado S, LiVolsi VA. Primary spindle cell lesions of the thyroid gland: an overview. Am J Clin Pathol. 2006;125(suppl):S95-S123.
Miettinen M, Franssila KO. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma. Hum Pathol. 2000;31(9):1139–1145.
Nonaka D, Dhiriboga L, Soslow R, et al. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol. 2008;21(2):192–200.
Elliott DD, Sherman SL, Bussaldy NL, et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008;39(1):15–20.
Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol. 2004;15(4):319–327.
Begum S, Rosenbaum E, Henrique R, et al. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol. 2004;17(11):1359–1363.
Hunt JL, Tometsko M, LiVolsi V, et al. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol. 2003;27(12):1559–1564.
Sala E, Mologni L, Truffa S, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res. 2008;6(5):751–759.
Leboeuf R, Baumgartner JE, Benezra M, et al. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab. 2008;93(6):2194–2201.
Hoffmann S, Burchert A, Weinderlich A, et al. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine. 2007;31(2):105–113.
Pennell NA, Daniels GH, Haddad Ri, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18(3):317–323.
Stenner F, Liewen H, Zweller M, et al. Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci. 2008;99(9):1847–1852.
Salvatore G, DeFalco V, Salerno P, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res. 2006;12(5):1623–1629.
Quiros RM, Ding H, Gattuso P, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005;103(11):2261–2268.
Nikiforova MN, Kimura EJ, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88(11):5399–5404.
Wang HM, Huang YU, Huang JS, et al. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann Surg Oncol. 2007;14(10):3011–3018.
Santarpia L, El Naggar AK, Cote G, et al. PI3K/Akt and Ras/Raf-MAPK pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2008;93(1):278–284.
Costa AM, Herrerro A, Fresno MF, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2008;68(4):618–634.
Rodrigues RF, Roque L, Rosa-Santos J, et al. Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer. 2004;90(2):492–496.
Miura D, Wada N, Chin K, et al. Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization. Thyroid. 2003;13(3):283–290.
Lee JJ, Au AY, Foukakis J, et al. Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. Endocr Relat Cancer. 2008;15(3):801–815.
Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93(8):3106–3116.
Kitamura Y, Ahimiu K, Ito K, et al. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer. 2000;27(3):244–251.
Fagin JA, Matsuo L, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest. 1993;91(1):179–184.
Sera N, Ashizawa K, Ando T, et al. Anaplastic changes associated with p53 gene mutation in differentiated thyroid carcinoma after insufficient radioactive iodine (131I) therapy. Thyroid. 2000;10(11):975–979.
Hosal SA, Apel R, Freeman JL, et al. Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior. Endocr Pathol. 1997;8(1):21–28.
Salvatore D, Celletti A, Fabien N, et al. Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours. Eur J Endocrinol. 1996;134(2):177–183.
Zafon C, Obois G, Castelivi J, et al. Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology. 2007;50(2):225–231.
Nakamura N, Carney Ja, Jin L, et al. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest. 2005;85(9):1065–1075.
Xing M, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 2004;64(5):1664–1668.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Hunt, J.L., LiVolsi, V.A. (2010). Poorly Differentiated and Undifferentiated Thyroid Carcinomas. In: Hunt, J. (eds) Molecular Pathology of Endocrine Diseases. Molecular Pathology Library, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-1707-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1707-2_10
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-1706-5
Online ISBN: 978-1-4419-1707-2
eBook Packages: MedicineMedicine (R0)